Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why VIVUS' Shares Slimmed Down

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Investors of anti-obesity drugmaker VIVUS (Nasdaq: VVUS  ) witnessed the company getting share-based liposuction, with shares down as much as 26%, following disappointing third-quarter earnings results.

So what: For the quarter, VIVUS' loss nearly quintupled to $40.4 million from $8.6 million in the year-ago quarter as marketing expenses for Qsymia, its anti-obesity drug, have risen dramatically. More damning for VIVUS, sales for the potential blockbuster have limped out of the gate with the company recording a miserable $41,000 in revenue. According to Bloomberg, VIVUS' management notes that patients are simply abandoning their prescriptions of the drug at the pharmacy counter once they realize they're paying the majority of the cost out of their own pockets.

Now what: Talk about a few weeks to forget about for VIVUS shareholders. First, Qsymia was denied approval in Europe by the European Medicines Agency, and now sales of the drug are struggling out of the gate. Part of this can be pointed to its lack of a marketing partner which I pointed out as a serious flaw weeks ago. Arena Pharmaceuticals (Nasdaq: ARNA  ) , my pick to win the lion's share of the anti-obesity market, has partnered with Eisai (NASDAQOTH: ESALY  ) , giving up some of its potential revenue, but locking in an experienced marketing team. Arena's Belviq also has a chance to lock up EMA approval of its drug and garner the international revenue that VIVUS could not. With few other competitors on the horizon -- let's face it, Orexigen Therapeutics' (Nasdaq: OREX  ) Contrave is still two years from market even if it breezes through safety trials -- Arena appears poised to take the lead and VIVUS may need to start begging for a marketing partner.

Will VIVUS be left in the dust by Arena Pharmaceuticals? Find out the answer to this question and much more by getting your copy of our latest premium research report on VIVUS. Packed with in-depth analysis on the opportunities and threats facing VIVUS -- and complete with a year of regular updates -- this report will give you the tools you need to make smart long-term decisions. Click here to get your copy.

Read/Post Comments (1) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 06, 2012, at 2:09 PM, Paulson545 wrote:

    This is becoming more like a Spam site than an investment site. This article give very little information and no buy or sell info. JMHO

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2098247, ~/Articles/ArticleHandler.aspx, 10/22/2016 9:34:57 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 12 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
ARNA $1.57 Down -0.02 -1.26%
Arena Pharmaceutic… CAPS Rating: **
VVUS $1.10 Down -0.01 -0.90%
VIVUS CAPS Rating: **
OREX $2.82 Up +0.04 +1.44%
Orexigen Therapeut… CAPS Rating: *